BTIG Research Reaffirms Buy Rating for Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences (NYSE:EW)‘s stock had its “buy” rating restated by analysts at BTIG Research in a research report issued on Friday, Benzinga reports. They currently have a $110.00 price target on the medical research company’s stock. BTIG Research’s price objective suggests a potential upside of 26.88% from the stock’s previous close.

EW has been the subject of a number of other reports. Evercore restated an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $87.00 to $101.00 in a research report on Friday, July 24th. Truist Financial upped their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Finally, UBS Group started coverage on Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a “buy” rating and a $110.00 target price on the stock. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $86.69 on Friday. The firm has a market capitalization of $49.92 billion, a P/E ratio of 49.82, a P/E/G ratio of 2.26 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The stock’s 50-day simple moving average is $89.36 and its two-hundred day simple moving average is $85.80. Edwards Lifesciences has a twelve month low of $72.30 and a twelve month high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. During the same period in the prior year, the business earned $0.67 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts anticipate that Edwards Lifesciences will post 3 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel Lippis sold 619 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the company’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the transaction, the senior vice president owned 14,868 shares of the company’s stock, valued at $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,045 shares of company stock worth $457,749 over the last quarter. Corporate insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in Edwards Lifesciences in the 2nd quarter worth $5,318,092,000. Varma Mutual Pension Insurance Co bought a new stake in Edwards Lifesciences during the second quarter valued at about $11,168,000. Norges Bank purchased a new stake in Edwards Lifesciences in the fourth quarter worth about $803,686,000. Conway Capital Management Inc. purchased a new stake in Edwards Lifesciences in the second quarter worth about $954,000. Finally, TD Asset Management Inc raised its stake in shares of Edwards Lifesciences by 6.4% in the fourth quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock worth $66,335,000 after buying an additional 47,051 shares during the period. 79.46% of the stock is owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.